真实世界中联用丙戊酸盐对奥氮平血药浓度的影响

打开文本图片集

[摘要] 目的 了解真实世界中联用丙戊酸盐对奥氮平血药浓度的影响。方法 调查2018年1月至2020年7月浙江省绍兴市第七人民医院住院服用奥氮平并有血药浓度检测结果的患者，采用倾向评分匹配，对联合使用丙戊酸盐组（联用组）和未联用丙戊酸盐组（对照组）进行1∶1匹配，并对匹配后的数据进行分析。结果 1796例进入统计，428对患者匹配成功，对匹配后的数据分析，结果显示联用组的奥氮平血药浓度中位数较对照组低22.83%（P

[关键词] 丙戊酸盐;奥氮平;血药浓度;倾向得分匹配

[中图分类号] R749          [文献标识码] B          [文章编号] 1673-9701（2022）06-0099-05

[Abstract] Objective To understand the effect of combined valproic acid on the plasma concentration of olanzapine in the real world. Methods Inpatients who took olanzapine with plasma concentration test results from January 2018 to July 2020 in Shaoxing 7th People′s Hospital in Zhejiang Province were surveyed. The propensity score matching method was used to match the combined valproic acid group （the combined group） and the non-combined valproic acid group （the control group） by 1∶1， and the matched data were analyzed. Results A total of 1796 cases were counted， and 428 pairs of patients were successfully matched. The analysis of the matched data showed that the median plasma concentration of olanzapine in the combination group was 22.83% lower than that in the control group （P

[Key words] Valproic acid; Olanzapine; Plasma concentration; Propensity score matching

奥氮平是第二代抗精神病药，在精神分裂症和双相障碍的治疗中曾长期作为一线治疗药物，仅在近年来因其对代谢的影响等原因降为二线推荐药物[1-4]，而丙戊酸盐作为一线的心境稳定剂，常联合抗精神病药用于治疗双相障碍，其中与奥氮平的联合使用也较为常见[2，3，5]。（剩余7356字）